Which has higher valuation and earnings, ASND or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 20.18 -$258M $12.89 20.44 Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Does the media refer more to ASND or PBLS?

In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Ascendis Pharma A/S's score of 0.88 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, BBIO or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $713.07M 19.86 -$724.93M -$3.57 N/A Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Is BBIO or PBLS more profitable?

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% Parabilis Medicines N/A N/A N/A

Does the media favor BBIO or PBLS?

In the previous week, BridgeBio Pharma had 10 more articles in the media than Parabilis Medicines. MarketBeat recorded 13 mentions for BridgeBio Pharma and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat BridgeBio Pharma's score of 0.36 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PBLS or EXEL?

Exelixis has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines $148K 30,783.09 N/A N/A N/A Exelixis $2.44B 5.71 $782.57M $3.18 17.65

Does the media favor PBLS or EXEL?

In the previous week, Exelixis had 24 more articles in the media than Parabilis Medicines. MarketBeat recorded 27 mentions for Exelixis and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Exelixis' score of 0.54 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive

Which has better earnings & valuation, SMMT or PBLS?

Parabilis Medicines has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Is SMMT or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Parabilis Medicines N/A N/A N/A

Does the media favor SMMT or PBLS?

In the previous week, Summit Therapeutics had 6 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Summit Therapeutics and 3 mentions for Parabilis Medicines. Summit Therapeutics' average media sentiment score of 1.12 beat Parabilis Medicines' score of 0.92 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MDGL or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals $958.40M 12.88 -$288.28M -$12.89 N/A Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Does the media refer more to MDGL or PBLS?

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Parabilis Medicines (PBLS) Competitors

$36.88 +0.56 (+1.54%)

As of 09/11/2026 04:00 PM Eastern

Compare

PBLS vs. ASND, BBIO, EXEL, SMMT, and MDGL

Should you buy Parabilis Medicines stock or one of its competitors? Parabilis Medicines's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Ascendis Pharma A/S has a net margin of 70.99% compared to Parabilis Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Parabilis Medicines	N/A	N/A	N/A

Ascendis Pharma A/S presently has a consensus target price of $310.00, indicating a potential upside of 17.64%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines has lower revenue, but higher earnings than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.18	-$258M	$12.89	20.44
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Ascendis Pharma A/S's score of 0.88 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Parabilis Medicines on 9 of the 11 factors compared between the two stocks.

How does Parabilis Medicines compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Parabilis Medicines has lower revenue, but higher earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

In the previous week, BridgeBio Pharma had 10 more articles in the media than Parabilis Medicines. MarketBeat recorded 13 mentions for BridgeBio Pharma and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat BridgeBio Pharma's score of 0.36 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Parabilis Medicines	N/A	N/A	N/A

BridgeBio Pharma presently has a consensus target price of $102.61, indicating a potential upside of 41.65%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

BridgeBio Pharma beats Parabilis Medicines on 7 of the 12 factors compared between the two stocks.

How does Parabilis Medicines compare to Exelixis?

Parabilis Medicines (NASDAQ:PBLS) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Exelixis has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65

Exelixis has a net margin of 35.33% compared to Parabilis Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Exelixis	35.33%	42.17%	31.76%

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Parabilis Medicines currently has a consensus target price of $41.67, indicating a potential upside of 12.98%. Exelixis has a consensus target price of $50.07, indicating a potential downside of 10.79%. Given Parabilis Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe Parabilis Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38

In the previous week, Exelixis had 24 more articles in the media than Parabilis Medicines. MarketBeat recorded 27 mentions for Exelixis and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Exelixis' score of 0.54 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive

Summary

Exelixis beats Parabilis Medicines on 8 of the 12 factors compared between the two stocks.

How does Parabilis Medicines compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Summit Therapeutics had 6 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Summit Therapeutics and 3 mentions for Parabilis Medicines. Summit Therapeutics' average media sentiment score of 1.12 beat Parabilis Medicines' score of 0.92 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summit Therapeutics presently has a consensus target price of $25.91, indicating a potential upside of 47.63%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Parabilis Medicines	N/A	N/A	N/A

Summary

Summit Therapeutics beats Parabilis Medicines on 6 of the 10 factors compared between the two stocks.

How does Parabilis Medicines compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Parabilis Medicines has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Parabilis Medicines' return on equity of 0.00% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Parabilis Medicines	N/A	N/A	N/A

Parabilis Medicines has lower revenue, but higher earnings than Madrigal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals currently has a consensus target price of $699.64, indicating a potential upside of 30.90%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Madrigal Pharmaceuticals beats Parabilis Medicines on 7 of the 13 factors compared between the two stocks.

Get Parabilis Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBLS vs. The Competition

Export

Metric	Parabilis Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.49B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	N/A	14.25	275.24	25.29
Price / Sales	30,783.09	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	N/A	15.12	10.33	6.20
Net Income	N/A	-$22.86M	$3.50B	$358.50M
7 Day Performance	-8.76%	-4.34%	-3.32%	-2.35%
1 Month Performance	-1.42%	-0.02%	-0.41%	-2.77%
1 Year Performance	N/A	40.64%	19.21%	7.63%

Parabilis Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBLS Parabilis Medicines	2.6144 of 5 stars	$36.88 +1.5%	$41.67 +13.0%	N/A	$4.49B	$148K	N/A	145	Positive News
ASND Ascendis Pharma A/S	4.3801 of 5 stars	$261.23 +0.2%	$310.00 +18.7%	+33.3%	$16.27B	$814.57M	20.27	1,189	Analyst Forecast Insider Trade Analyst Revision
BBIO BridgeBio Pharma	3.4567 of 5 stars	$72.50 -4.7%	$101.53 +40.0%	+37.7%	$14.87B	$502.08M	N/A	839	Analyst Forecast
EXEL Exelixis	2.4691 of 5 stars	$57.43 -1.5%	$50.07 -12.8%	+43.6%	$14.45B	$2.32B	18.06	1,077	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.6754 of 5 stars	$17.00 -3.1%	$25.91 +52.4%	-5.6%	$13.99B	N/A	N/A	265	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBLS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Parabilis Medicines (PBLS) Competitors

PBLS vs. ASND, BBIO, EXEL, SMMT, and MDGL

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Summary

How does Parabilis Medicines compare to BridgeBio Pharma?

Summary

How does Parabilis Medicines compare to Exelixis?

Summary

How does Parabilis Medicines compare to Summit Therapeutics?

Summary

How does Parabilis Medicines compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Parabilis Medicines (PBLS) Competitors

PBLS vs. ASND, BBIO, EXEL, SMMT, and MDGL

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Is ASND or PBLS more profitable?

Do analysts rate ASND or PBLS?

Which has higher valuation and earnings, ASND or PBLS?

Does the media refer more to ASND or PBLS?

Summary

How does Parabilis Medicines compare to BridgeBio Pharma?

Which has stronger valuation & earnings, BBIO or PBLS?

Does the media favor BBIO or PBLS?

Do institutionals & insiders believe in BBIO or PBLS?

Is BBIO or PBLS more profitable?

Do analysts rate BBIO or PBLS?

Summary

How does Parabilis Medicines compare to Exelixis?

Which has higher valuation and earnings, PBLS or EXEL?

Is PBLS or EXEL more profitable?

Do institutionals & insiders believe in PBLS or EXEL?

Do analysts recommend PBLS or EXEL?

Does the media favor PBLS or EXEL?

Summary

How does Parabilis Medicines compare to Summit Therapeutics?

Does the media favor SMMT or PBLS?

Which has better earnings & valuation, SMMT or PBLS?

Do insiders and institutionals believe in SMMT or PBLS?

Do analysts rate SMMT or PBLS?

Is SMMT or PBLS more profitable?

Summary

How does Parabilis Medicines compare to Madrigal Pharmaceuticals?

Is MDGL or PBLS more profitable?

Which has higher valuation & earnings, MDGL or PBLS?

Do insiders and institutionals believe in MDGL or PBLS?

Does the media refer more to MDGL or PBLS?

Do analysts rate MDGL or PBLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools